☆ 4.4 Letter

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia

HAEMATOLOGICA (2014)

Journal

HAEMATOLOGICA

Volume 99, Issue 10, Pages E185-E187

Publisher

FERRATA STORTI FOUNDATION

DOI: 10.3324/haematol.2014.109827

Keywords

daunorubicin intensification; CBF; AML

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Transcriptional Response to Standard AML Drugs Identifies Synergistic Combinations

Piyush More, Joelle Aurelie Mekontso Ngaffo, Ute Goedtel-Armbrust, Patricia S. Haehnel, Udo F. Hartwig, Thomas Kindler, Leszek Wojnowski

Summary: We analyzed gene expression changes in AML cell lines in response to standard AML drugs, identified treatment-relevant genes and pathways, and showed that drug response can be enhanced by pharmacological mimicking of these changes. The synergistic effect was observed in other cell lines and confirmed in public cytotoxicity data.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Hematology

Emerging therapies for inv(16) AML

Sridevi Surapally, Daniel G. Tenen, John A. Pulikkan

Summary: This review focuses on the key role of CBF beta-SMMHC in AML and recent advances in therapeutic strategies targeting CBF beta-SMMHC in inv(16) AML.

BLOOD (2021)

Add to Collection

Article Oncology

High Throughput Fluorescence-Based In Vitro Experimental Platform for the Identification of Effective Therapies to Overcome Tumour Microenvironment-Mediated Drug Resistance in AML

Yoana Arroyo-Berdugo, Maria Sendino, David Greaves, Natalia Nojszewska, Orest Idilli, Chi Wai So, Lucy Di Silvio, Ruby Quartey-Papafio, Farzin Farzaneh, Jose Antonio Rodriguez, Yolanda Calle

Summary: The interactions between AML leukemic stem cells and the bone marrow microenvironment are important for AML progression and drug resistance. In this study, a fluorescence-based in vitro co-culture system was developed to accurately assess the effect of drugs on AML cells and the cytoprotective BM microenvironment. The system identified several compounds that can overcome BM stroma-mediated drug resistance and provided insights for developing improved therapeutics targeting AML cells within the protective BM microenvironment.

CANCERS (2023)

Add to Collection

Article Plant Sciences

Comparative transcriptomics analysis reveals a calcineurin B-like gene to positively regulate constitutive and acclimated freezing tolerance in potato

Lin Chen, Hongbo Zhao, Ye Chen, Fujing Jiang, Feiyan Zhou, Qing Liu, Yongqi Fan, Tiantian Liu, Wei Tu, Dirk Walther, Botao Song

Summary: This study identified the key gene SaCBL1-like that confers freezing tolerance in potato and revealed its functional mechanism. This is of great significance for potato breeding in cold climates.

PLANT CELL AND ENVIRONMENT (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Phaeochromycins I-K, Three Methylene-Bridged Dimeric Polyketides from Streptomyces sp. 166#

Yibo Xu, Dongyang Wang, Qianqian Lv, Peng Fu, Ying Wang, Weiming Zhu

Summary: Three new dimeric polyketides, phaeochromy-cins I-K (1-3) and a known polyketide phaeochro-mycin F (4), were isolated from the culture broth of a Streptomyces sp. 166# derived from the saline Qinghai-Tibet Plateau permafrost soil. The structures were determined using NMR and HRESIMS data. Compounds 2 and 3 showed selective antiproliferative activity against H1299 and HUCCT1 cell lines, with IC50 values ranging from 8.83 to 10.52 μM.

ACS OMEGA (2023)

Add to Collection

Article Oncology

Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux

Rachael Nicholson, Ana Catarina Menezes, Aleksandra Azevedo, Adam Leckenby, Sara Davies, Claire Seedhouse, Amanda Gilkes, Steve Knapper, Alex Tonks, Richard L. Darley

Summary: This study found that PKC epsilon is significantly overexpressed in acute myeloid leukemia (AML) and is associated with reduced complete remission induction and disease-free survival. Additionally, PKC epsilon overexpression confers resistance to the chemotherapeutic agent daunorubicin by upregulating the expression of the efflux pump P-GP.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Education, Scientific Disciplines

Optimizing outcomes in secondary AML

Andrew Matthews, Keith W. Pratz

Summary: Acute myeloid leukemia (AML) secondary to antecedent hematologic disorder or prior therapeutics for cancer is a challenging type of leukemia with inferior outcomes. While conventional therapy with cytarabine-based chemotherapy has been the mainstay of care for the past 30 years, recent studies have shown that novel therapies, such as liposomal cytarabine/daunorubicin and venetoclax-based therapies, may lead to improved outcomes. However, mutations in TP53 remain a challenge and there is a need for immune-targeted therapies. Allogeneic transplant is currently the only known curative therapy, but high-risk molecular features of secondary AML are associated with inferior outcomes even after transplant. The optimal approach to secondary AML is yet to be determined.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)

Add to Collection

Article Hematology

Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML

Kavitha Ramaswamy, Peter G. Steinherz, Anurag K. Agrawal, Christopher J. Forlenza, Audrey Mauguen, Mikhail Roshal, Tanya Trippett, Nancy A. Kernan, Maria Luisa Sulis, Neerav Shukla

Summary: Effective reinduction regimens are essential for children with relapsed and refractory AML. A phase 2 trial of TVTC reinduction in a bicenter cohort of young AML patients demonstrated a high overall response rate and successful bridging to stem cell transplantation, making it a promising salvage option for this patient population.

BLOOD ADVANCES (2022)

Add to Collection

Article Engineering, Chemical

Guanine-Based DNA Biosensor Amplified with Pt/SWCNTs Nanocomposite as Analytical Tool for Nanomolar Determination of Daunorubicin as an Anticancer Drug: A Docking/Experimental Investigation

Hassan Karimi-Maleh, Marzieh Alizadeh, Yasin Orooji, Fatemeh Karimi, Mehdi Baghayeri, Jalal Rouhi, Somayeh Tajik, Hadi Beitollahi, Shilpi Agarwal, Vinod K. Gupta, Saravanan Rajendran, Sadegh Rostamnia, Li Fu, Farshad Saberi-Movahed, Samira Malekmohammadi

Summary: In this study, a daunorubicin electrochemical biosensor was successfully developed using ds-DNA as the biorecognition element and Pt/SWCNTs/GCE as the sensor. The sensor showed high sensitivity and accuracy in determining daunorubicin, making it a promising tool for analyzing this important anticancer drug.

INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH (2021)

Add to Collection

Article Biophysics

Non-T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT

Arnon Nagler, Myriam Labopin, Xiao-jun Huang, Didier Blaise, William Arcese, Mercedes Colorado Araujo, Gerard Socie, Edouard Forcade, Fabio Ciceri, Jonathan Canaani, Sebastian Giebel, Eolia Brissot, Jaime Sanz Caballer, Ali Bazarbachi, Ibrahim Yakoub-Agha, Mohamad Mohty

Summary: This study compared the transplantation outcomes of AML patients undergoing HaploSCT in CR1 after one or two induction chemotherapy courses. The results showed that patients achieving CR1 with two induction courses had a higher relapse incidence and inferior leukemia-free survival, overall survival, and GVHD-free, relapse-free survival compared to those achieving CR1 with one induction course.

BONE MARROW TRANSPLANTATION (2022)

Add to Collection

Article Medicine, General & Internal

Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)

Rathnamitreyee Vegunta, Ronen Harel, Amir Steinberg

Summary: Chemotherapy remains the standard treatment for AML, but the optimal dose and safety profile when combined with new therapies like gemtuzumab-ozogamicin and FLT3 inhibitors are still being studied. Limited data suggest that intensified daunorubicin combined with gemtuzumab-ozogamicin may be effective for AML treatment, but may result in a significant decrease in platelet count.

CUREUS JOURNAL OF MEDICAL SCIENCE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Rational Design of Daunorubicin C-14 Hydroxylase Based on the Understanding of Its Substrate-Binding Mechanism

Jing Zhang, Ling-Xiao Gao, Wei Chen, Jian-Jiang Zhong, Chao Qian, Wen-Wen Zhou

Summary: Doxorubicin, a widely used antitumor drug, is currently produced through a chemical conversion method, which is costly and environmentally polluting. In this study, we expressed and optimized the key enzyme, cytochrome daunorubicin C-14 hydroxylase, for doxorubicin production. Through rational design, we obtained a mutant enzyme, DoxA(P88Y), which showed a 56% increase in bioconversion efficiency compared to the wild-type enzyme. Molecular dynamics simulation revealed the enhanced binding stability between the mutant enzyme and the substrate, daunorubicin, contributing to the improved catalytic activity. This work provides a foundation for further development of doxorubicin and facilitates its industrial production.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Food Science & Technology

Global dietary convergence from 1970 to 2010 altered inequality in agriculture, nutrition and health

Winnie Bell, Keith Lividini, William A. Masters

Summary: This study found that global food-system inequality has generally declined, but changes in different variables varied significantly. Despite similar nutritional needs, humans globally face large differences in natural resource endowments and local food production.

NATURE FOOD (2021)

Add to Collection

Article Medicine, General & Internal

Assessment of Arterial Transit Time and Cerebrovascular Reactivity in Moyamoya Disease by Simultaneous PET/MRI

Kenji Takata, Hirohiko Kimura, Shota Ishida, Makoto Isozaki, Yoshifumi Higashino, Ken-Ichiro Kikuta, Hidehiko Okazawa, Tetsuya Tsujikawa

Summary: The relationship between MRI-arterial spin labeling (ASL) parameters and PET-cerebral blood flow (CBF)/cerebrovascular reactivity (CVR) was investigated in Moyamoya disease. The results showed significant correlations between ASL parameters and PET-CBF/PET-CVR. Furthermore, ASL-ATT in the MCA territories was found to be related to CVR.

DIAGNOSTICS (2023)

Add to Collection

Article Plant Sciences

Involvement of CBF in the fine-tuning of litchi flowering time and cold and drought stresses

Xiaozhen Shan, Yun Yang, Shuoqi Wei, Chao Wang, Weishi Shen, Hou-bin Chen, Ji-yuan Shen

Summary: Litchi is an economically important fruit tree in southern China and is widely cultivated in subtropical regions. In this study, the researchers identified LcCBF2 and LcCBF3 as upstream activators of LcMFT, and proposed their contribution to the fine-tuning of flowering time. Ectopic overexpression of LcCBF2 and LcCBF3 in Arabidopsis resulted in delayed flowering and increased freezing and drought tolerance.

FRONTIERS IN PLANT SCIENCE (2023)

Add to Collection

Article Hematology

Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

Naval G. Daver, Monique Dail, Jacqueline S. Garcia, Brian A. Jonas, Karen W. L. Yee, Kevin R. Kelly, Norbert Vey, Sarit Assouline, Gail J. Roboz, Stefania Paolini, Daniel A. Pollyea, Agostino Tafuri, Joseph M. Brandwein, Arnaud Pigneux, Bayard L. Powell, Pierre Fenaux, Rebecca L. Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Cherie Green, Marion G. Ott, Wan-Jen Hong, Marina Y. Konopleva, Michael Andreeff

Summary: This phase 1b trial evaluated the use of venetoclax-idasanutlin in patients with relapsed/refractory acute myeloid leukemia ineligible for cytotoxic chemotherapy. The trial showed that venetoclax-idasanutlin is a feasible and effective treatment option for these patients, with manageable safety profile.

BLOOD (2023)

Add to Collection

Article Oncology

Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia

Alban Canali, Ines Vergnolle, Sarah Bertoli, Laetitia Largeaud, Marie-Laure Nicolau, Jean-Baptiste Rieu, Suzanne Tavitian, Francoise Huguet, Muriel Picard, Pierre Bories, Jean Philippe Vial, Nicolas Lechevalier, Marie Christine Bene, Isabelle Luquet, Veronique Mansat-De Mas, Eric Delabesse, Christian Recher, Francois Vergez

Summary: This study aims to evaluate the predictive effect of clustering analysis on residual disease in patients with acute myeloid leukemia (AML). The results indicate that residual disease assessment using multiparametric flow cytometry in AML patients can predict patient survival, and the analysis of LSC MRD in the chemotherapy-resistant subpopulation is more clinically relevant.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Hematology

Overlapping features of therapy-related and de novo NPM1-mutated AML

Jad Othman, Manja Meggendorfer, Enrico Tiacci, Christian Thiede, Richard Schlenk, Richard Dillon, Sebastian Stasik, Alessandra Venanzi, Sarah Bertoli, Eric Delabesse, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Amanda F. Gilkes, Ian Thomas, Maria Teresa Voso, Alessandro Rambaldi, Lorenzo Brunetti, Vincenzo M. Perriello, Vibeke Andresen, Bjorn T. Gjertsen, Maria Paola Martelli, Christian Recher, Christoph Roellig, Martin Bornhaeuser, Hubert Serve, Carsten Mueller-Tidow, Claudia D. Baldus, Tortsten Haferlach, Nigel Russell, Brunangelo Falini

Summary: The characteristics of therapy-related NPM1-mutated AML (t-NPM1 AML) were found to be similar to de novo NPM1-mutated AML (dn-NPM1 AML) in terms of genetics, transcriptional profile, and clinical outcomes. However, t-NPM1 AML showed better overall survival and relapse-free survival compared to t-AML.

BLOOD (2023)

Add to Collection

Editorial Material Hematology

Acute promyelocytic leukaemia associated with atypical basophilia

Jean-Baptiste Rieu, Alban Canali, Emilie Thene, Suzanne Tavitian, Sarah Bertoli

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Hematology

Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy

Thomas Pabst, Norbert Vey, Lionel Ades, Ulrike Bacher, Mario Bargetzi, Samson Fung, Gianluca Gaidano, Domenica Gandini, Anna Hultberg, Amy Johnson, Xuewen Ma, Rouven Muller, Kerri Nottage, Cristina Papayannidis, Christian Recher, Carsten Riether, Priya Shah, Jeffrey Tryon, Liang Xiu, Adrian F. Ochsenbein

Summary: Cusatuzumab, a high-affinity anti-CD70 monoclonal antibody, has shown preliminary efficacy and tolerability when combined with azacitidine in patients with newly diagnosed AML ineligible for intensive chemotherapy. The recommended phase II dose of cusatuzumab was determined to be 10 mg/kg. Objective responses were achieved in 50% of patients, with a median duration of response of 4.5 months and a median overall survival of 11.5 months. The most common treatment-emergent adverse events were infections and hematologic toxicities. Further investigation of cusatuzumab combined with current standard-of-care therapy is ongoing.

HAEMATOLOGICA (2023)

Add to Collection

Article Cell Biology

Prognostic Immune Effector Signature in Adult Acute Lymphoblastic Leukemia Patients Is Dominated by ?d T Cells

Anne-Charlotte Le Floch, Marie-Sarah Rouviere, Nassim Salem, Amira Ben Amara, Florence Orlanducci, Norbert Vey, Laurent Gorvel, Anne-Sophie Chretien, Daniel Olive

Summary: This study explored the impact of circulating ?d T-cell alterations on prognosis in newly diagnosed adult ALL patients. They found common alterations in CD8(+) T cells and ?d T cells of relapsed patients, including accumulation of early stage differentiation and increased expression of BTLA and CD73. The circulating ?d T-cell signature and Vd2 T-cell alterations were found to strongly discriminate patients by relapse status. These findings suggest the importance of Gd T cells, especially Vd2 T cells, in T-cell immunity and provide a rationale for further monitoring and enhancing Vd2 T cells in ALL.

CELLS (2023)

Add to Collection

Article Biophysics

Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome

Samia Harbi, Louison Brac de la Perriere, Benjamin Bouchacourt, Sylvain Garciaz, Thomas Pagliardini, Boris Calmels, Maud Cecile, Anne-Charlotte Lefloch, Yosr Hicheri, Marie-Anne Hospital, Sabine Furst, Claude Lemarie, Cecile Braticevic, Faezeh Legrand, Elena Bekrieva, Pierre-Jean Weiller, Christian Chabannon, Norbert Vey, Didier Blaise, Raynier Devillier

Summary: This article reports the experience of peripheral blood Haplo-SCT in AML and MDS patients aged 70 years and over. The results show that this treatment method is feasible and provides long-term disease control and survival in this age group.

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Article Biophysics

GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation

Francois Dachy, Sabine Furst, Boris Calmels, Thomas Pagliardini, Samia Harbi, Benjamin Bouchacourt, Anne Calleja, Claude Lemarie, Aude Collignon, Guillaume Morel, Faezeh Legrand, Elena Bekrieva, Angela Granata, Pierre Jean Weiller, Christian Chabannon, Jean Marc Schiano, Norbert Vey, Didier Blaise, Raynier Devillier

BONE MARROW TRANSPLANTATION (2023)

Add to Collection

Letter Hematology

Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study

Maya Belhadj, Barbara Burroni, Olivier Kosmider, Lise Willems, Marie Temple, Sarah Bertoli, Corentin Orvain, Pierre-Yves Dumas, Celine Berthon, Ludovic Gabellier, Ambroise Marcais, Emmanuel Raffoux, Cecile Pautas, Alexis Genthon, Justine Decroocq, Rudy Birsen, Jerome Tamburini, Didier Bouscary, Adrien Contejean

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Medicine, Research & Experimental

Downregulation of stromal syntenin sustains AML development

Raphael Leblanc, Rania Ghossoub, Armelle Goubard, Remy Castellano, Joanna Fares, Luc Camoin, Stephane Audebert, Marielle Balzano, Berna Bou-Tayeh, Cyril Fauriat, Norbert Vey, Sylvain Garciaz, Jean-Paul Borg, Yves Collette, Michel Aurrand-Lions, Guido David, Pascale Zimmermann

Summary: This study reveals a vicious signaling loop potentially at the heart of AML-stroma crosstalk and unexpected tumor-suppressive effects of syntenin that need to be considered during systemic targeting of syntenin in cancer therapy.

EMBO MOLECULAR MEDICINE (2023)

Add to Collection

Editorial Material Mycology

Disseminated Scedosporium Invasive Fungal Infection in Critically ill Newly Diagnosed Acute Myeloid Leukemia Patient Complicated with Cerebritis

Colombe Saillard, Magali Bisbal, Morgan Avenin, Pierre Lehmann, Antoine Sannini, Laurent Chow-Chine, Luca Servan, Frederic Gonzalez, Evelyne d'Incan, Norbert Vey, Djamel Mokart

MYCOPATHOLOGIA (2023)

Add to Collection

Meeting Abstract Oncology

A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH, in advanced myeloid malignancies

Courtney D. DiNardo, Pau Montesinos, Lina Benajiba, Ana Triguero, Christian Recher, Andre C. Schuh, Mael Heiblig, Ashish Bajel, Arnaud Pigneux, Juan M. Alonso-Domiguez, Amir T. Fathi, Carolyn Grove, Hsin-An Hou, Michael Heuser, Sarit Assouline, Shaun Fleming, Dong-Yeop Shin, Kendra Sweet, Olatoyosi Odenike, Jessica Altman, Melissa Gaik Ming Ooi, Lao Zhentang, Nobert Vey, Joshua Zeidner, Amandeep Salhotra, Eunice Wang, Gary Schiller, Kimmo Porkka, Tsila Zuckerman, Violaine Havelange, Brian A. Jonas, Sujaatha Narayanan, Jun Ho Jang, Je-Hwan Lee, Anna M. Szpurka, Dana Heirich, Hsiao Rong Chen, Violet Hanft, Junjie Zhao, Ivelina Gueorguieva, Yin Zhang, Eytan M. Stein

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Hematology

LONG-TERM SURVIVAL OF ACUTE MYELOID LEUKEMIA RESPONDING PATIENT WHO DISCONTINUED AZACYTIDINE AND/OR VENETOCLAX: A RETROSPECTIVE MULTICENTER STUDY FROM THE FRENCH INNOVATIVE LEUKEMIA ORGANIZATION (FILO)

S. Garciaz, P. -Y. Dumas, S. Bertoli, J. Decroocq, A. Belhabri, C. Simand, K. Laribi, A. Santagostino, M. Carre, A. Schmidt, G. Aspas Requena, C. Himberlin, P. Peterlin, M. -A. Hospital, A. Pigneux, N. Vey, C. Recher

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Meeting Abstract Hematology

EFFICACY OF VENETOCLAX/AZACITIDINE SALVAGE THERAPY COMPARED TO AZACITIDINE MONOTHERAPY FOR PATIENT WITH FIRST RELAPSED OR REFRACTORY ACUTE MYELOID LEUKAEMIA

C. Petit, B. Mohty, Y. Hicheri, C. Saillard, F. Villetard, V. Maisano, A. Charbonnier, J. Rey, E. D'Incan, N. Vey, M. -A. Hospital, S. Garciaz

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Article Medicine, Research & Experimental

Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases

Vincent Jachiet, Laure Ricard, Pierre Hirsch, Florent Malard, Laurent Pascal, Odile Beyne-Rauzy, Pierre Peterlin, Alexandre Thibault Jacques Maria, Norbert Vey, Maud D'Aveni, Marie-Pierre Gourin, Sophie Dimicoli-Salazar, Anne Banos, Stefan Wickenhauser, Louis Terriou, Benoit De Renzis, Eric Durot, Shanti Natarajan-Ame, Anne Vekhoff, Laurent Voillat, Sophie Park, Julien Vinit, Celine Dieval, Azeddine Dellal, Vincent Grobost, Lise Willems, Julien Rossignol, Eric Solary, Olivier Kosmider, Nicolas Dulphy, Lin Pierre Zhao, Lionel Ades, Pierre Fenaux, Olivier Fain, Mohamad Mohty, Beatrice Gaugler, Arsene Mekinian

Summary: Background systemic inflammatory and autoimmune diseases (SIADs) occur in a significant proportion of myelodysplastic syndrome (MDS) patients. The recently identified VEXAS syndrome, associated with somatic mutations in UBA1, is characterized by severe inflammatory conditions and hematological abnormalities, including MDS. However, the mechanisms underlying the association between MDS and SIADs are largely unknown. This study aimed to evaluate myeloid immune cell subsets in MDS patients with and without SIAD and compare them to healthy controls.

CLINICAL AND EXPERIMENTAL MEDICINE (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.